NTLA — Intellia Therapeutics, Inc.

Summary of Intellia Therapeutics Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: As of December 31, 2025, cash, cash equivalents, and marketable securities totaled $605.1 million, down from $861.7 million a year earlier. This is expected to fund operations into the second half of 2027.
• Collaboration Revenue: Increased to $23 million in Q4 2025 from $12.9 million in Q4 2024, driven by the termination of a collaboration with SparingVision and increased reimbursements from Regeneron.
• R&D Expenses: Decreased to $88.7 million from $116.9 million year-over-year, attributed to reduced employee-related expenses and research costs, despite increased clinical trial expenses for lonvo-z.
• G&A Expenses: Remained stable at $33.1 million, slightly up from $32.4 million in the previous year.
• Net Loss: Reduced to $95.8 million from $128.9 million in Q4 2024.

2. Strategic Updates and Business Highlights

• Clinical Trials:
  • lonvo-z: Phase 3 trial (HAELO) completed enrollment with 80 patients ahead of schedule. Anticipated top-line data by mid-2026 and a planned BLA submission in the second half of 2026.
  • nex-z: Enrollment in the MAGNITUDE trial for ATTR amyloidosis was halted due to safety concerns but was lifted for MAGNITUDE-2, with new safety protocols implemented.
• Patient Engagement: High interest in lonvo-z among patients and healthcare providers, with 99% of surveyed patients expressing willingness to take the treatment if approved.
• Commercial Readiness: The company is preparing for the potential launch of lonvo-z, focusing on scaling the sales and reimbursement teams and finalizing distribution and pricing strategies.

3. Forward Guidance and Outlook

• Intellia expects to complete enrollment in MAGNITUDE-2 in the second half of 2026 and anticipates significant milestones with lonvo-z leading to a potential launch in 2027.
• The company is optimistic about achieving a mid-single-digit market share for lonvo-z, which could significantly enhance cash flow and fund operations.

4. Bad News, Challenges, or Points of Concern

• Clinical Holds: The MAGNITUDE trial for ATTR amyloidosis faced a clinical hold due to elevated liver transaminases in a patient, raising concerns about safety and regulatory scrutiny.
• Safety Concerns: The company is addressing potential immune-mediated reactions linked to liver enzyme elevations, which could impact patient enrollment and trial outcomes.
• Market Competition: The competitive landscape includes other therapies for HAE, and the company must demonstrate superior efficacy and safety to gain market share.

5. Notable Q&A Insights

• FDA Engagement: The FDA has treated the HAE and ATTR programs as distinct, with different patient demographics influencing regulatory decisions.
• Commercial Strategy: Discussions with payers have been positive, with recognition of the unmet need in HAE therapies, although specific pricing discussions are still pending.
• Patient Population: The company believes that the demographics of the patient populations in the Phase 3 trials are largely representative of the broader HAE community, which should support comparability of results.
• Liver Injury Mechanism: There is ongoing investigation into the liver injury mechanism, with the company emphasizing that it does not expect these issues to affect other programs in its pipeline.

This summary encapsulates the key financial results, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a comprehensive overview of Intellia Therapeutics' current position and outlook.